>

Daniel Vasella - Novartis Honorary Chairman of the Board

<div class='circular--portrait' style='background:#2A0CD0;color: white;font-size:4em;padding-top: 25px;;'>NO</div>
NVS -- USA Stock  

Earning Report: 22nd of April 2020  

  Chairman
Dr. Daniel L. Vasella, M.D., is Honorary Chairman of the Board of Novartis Inc. He was Chairman of the Board of Directors of Novartis from February 1, 2010 until 2013. He was Chairman of the Chairman Committee at the Company. He resigned from his position as Chief Executive Officer of the Company on February 1, 2010. He had served as CEO and Executive Member of the Board of Directors of Novartis AG since the merger that created Novartis AG in 1996. He was appointed Company Chairman of the Board of Directors in 1999. Befor the Novartis AG merger, Dr. Vasella was CEO of Sandoz Pharma Ltd. and Member of the Sandoz Group Executive Committee. From 1988 to 1992, he was with Sandoz Pharmaceuticals Corporationrationration in the United States, prior to which he held a number of medical positions in Switzerland. Dr. Vasella is Member of the Board of Directors of PepsiCo, Inc. He is also Member of the International Board of Governors of the Peres Center for Peace in Israel, the International Business Leaders Advisory Council for the Mayor of Shanghai, the Global Health Program Advisory Panel of the Bill Melinda Gates Foundation, and is a foreign Honorary Member of the American Academy of Arts and Sciences. He is also Member of the Board of Trustees of the Carnegie Endowment for International Peace. In addition, Dr. Vasella serves as Member of several industry associations and educational institutions. Dr. Vasella graduated with a Medical Doctor title from Universitaet Bern in 1979
Age: 65    Ph.D    
41 61 324 1111  http://www.novartis.com
Vasella was honored with several awards, including the Harvard Business School Alumni Achievement Award and Appeal of Conscience Award, the AJ Congress Humanitarian Award, the Ordem Nacional do Cruzeiro do Sul, and holds the rank of Chevalier in the Ordre national de la Legion d'honneur . He was also awarded an honorary doctorate by the University of Basel.

Daniel Vasella Latest Insider Activity

Management Efficiency

The company has 29.33 B in debt with debt to equity (D/E) ratio of 52.8 . This implies that the company may be unable to create cash to meet all of its financial commitments. Novartis AG has Current Ratio of 1.02 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

CHAIRMAN Since

Thibaut MongonJohnson Johnson
2018
Jennifer TaubertJohnson Johnson
2018
Jorge MesquitaJohnson Johnson
2016
Kenneth FrazierMerck Company
2011
Giovanni CaforioBristol Myers Squibb Company
2017
Ian ReadPfizer
2018
John MartinGilead Sciences
N/A
Sandra PetersonJohnson Johnson
2017
Moncef SlaouiGlaxoSmithKline PLC
2014
John LechleiterEli Lilly And Company
2016
Paulus StoffelsJohnson Johnson
2018
Paul BisaroAllergan Plc
2016
Ashley McEvoyJohnson Johnson
2018
Alex GorskyJohnson Johnson
2012
Daniel ODayGilead Sciences
2019
Joaquin DuatoJohnson Johnson
2018
Leif JohanssonAstrazeneca PLC
2012
Brenton SaundersAllergan Plc
2016
Lamberto AndreottiBristol Myers Squibb Company
2015

Company Summary

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was founded in 1895 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 103914 people.Novartis AG (NVS) is traded on BATS Exchange in USA. It is located in Lichtstrasse 35 and employs 103,914 people. Novartis AG was previously known as NOVARTIS AG and was traded on BATS Exchange under the symbol NVSEF. Novartis is listed under Pharmaceutical Products category by Fama And French industry classification.

Novartis AG Leadership Team

Ton Buechner, Non-Executive Independent DirectorView
Verena Briner, Non-Executive Independent Member of the BoardView
Chris Ilsley, President CEOView
Steven Baert, Chief People & Organization Officer, Member of the Executive CommitteeView
Richard Saynor, Chief Executive Officer of Sandoz, Member of the Executive CommitteeView
Richard Francis, Member of the Executive Committee and Division Head, SandozView
Daniel Vasella, Honorary Chairman of the BoardView
Pierre Landolt, Member of the Board of DirectorsView
Elizabeth Doherty, Non-Executive Independent DirectorView
Erwin Vanhaecke, Head Novartis Group QualityView
Elizabeth Barrett, CEO, Novartis OncologyView
Mark Fishman, Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR)View
Charlotte PamerWieser, Corporate SecretaryView
Shannon Klinger, Chief Risk and Compliance Officer, Group General CounselView
Samir Shah, Global Head Investor RelationsView
David Epstein, Member of the Executive Committee, Division Head, PharmaceuticalsView
Srikant Datar, Non-Executive Independent DirectorView
MarieFrance Tschudin, President of Novartis Pharmaceuticals, Member of the Executive CommitteeView
Simon Moroney, DirectorView
Francesco Balestrieri, Chief Executive Officer of Sandoz, Member of the Executive CommitteeView
Steffen Lang, Global Head of Novartis Technical Operations, Member of the Executive CommitteeView
Joerg Reinhardt, Independent Non-Executive Chairman of the BoardView
Paul Hudson, Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive CommitteeView
Brian McNamara, Member of the Management Board, Division Head, Novartis OTCView
Andrews C, Non-Executive Independent DirectorView
Michele Galen, Head CommunicationsView
Charles Sawyers, Non-Executive Independent Member of the BoardView
John Tsai, Head of Global Drug Development and Chief Medical Office, Member of the Executive CommitteeView
Dimitri Azar, Non-Executive Independent DirectorView
Frans Houten, Non-Executive Independent DirectorView
Nancy Andrews, Non-Executive Independent DirectorView
Susanne Schaffert, CEO Novartis Oncology, Member of the Executive CommitteeView
Enrico Vanni, Independent Non-Executive Vice Chairman of the BoardView
Bertrand Bodson, Chief Digital Officer, Member of the Executive CommitteeView
Robert Weltevreden, Head of Novartis Business Services (NBS), Member of the Executive CommitteeView
Andre Wyss, Member of the Executive Committee, Novartis Business Services and Country President for SwitzerlandView
Bruno Strigini, CEO of Novartis Oncology, Member of the Executive CommitteeView
Vasant Narasimhan, Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive CommitteeView
Alex Krauer, Honorary Chairman of the BoardView
Michael Ball, CEO of Alcon, Member of the Executive CommitteeView
Jeffrey George, Member of the Executive Committee and Division Head, SandozView
Patrice Bula, Non-Executive Independent DirectorView
Peter Kornicker, Chief Compliance OfficerView
Andreas Planta, Non-Executive Independent DirectorView
Joseph Jimenez, CEO, Member of the Executive CommitteeView
Ulrich Lehner, Vice Chairman of the Board of Directors, Non-Executive DirectorView
William Winters, Non-Executive Independent Member of the BoardView
Ann Fudge, Non-Executive Independent DirectorView
George Gunn, Member of the Executive Committee, Division Head, Novartis Animal Health of Head, Corporate ResponsibilityView
Paul Arkel, Head of Corporate Strategy and External AffairsView
James Bradner, President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive CommitteeView
Klaus Moosmayer, Chief Ethics, Risk and Compliance Officer, Member of the Executive CommitteeView
Felix Ehrat, General Counsel and General Counsel of Novartis International AgView
Harry Kirsch, Chief Financial Officer, Member of the Executive CommitteeView
Andrin Oswald, Member of the Executive Committee, Division Head, Vaccines and DiagnosticsView
Bridgette Heller, DirectorView

Stock Performance Indicators

Current Sentiment - NVS

Novartis AG Investor Sentiment

Predominant part of Macroaxis users are now bullish on Novartis AG. What is your trading attitude regarding investing in Novartis AG? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Please also try Money Managers module to screen money managers from public funds and etfs managed around the world.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page